Tech ID: 28923 / UC Case 2018-048-0

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 11,970,719 04/30/2024 2018-048

Additional Patent Pending

Brief Description

The CRISPR-Cas system is now understood to confer bacteria and archaea with acquired immunity against phage and viruses. CRISPR-Cas systems consist of Cas proteins, which are involved in acquisition, targeting and cleavage of foreign DNA or RNA, and a CRISPR array, which includes direct repeats flanking short spacer sequences that guide Cas proteins to their targets.  Class 2 CRISPR-Cas systems are streamlined versions in which a single Cas protein bound to RNA is responsible for binding to and cleavage of a targeted sequence. The programmable nature of these minimal systems has facilitated their use as a versatile technology that is revolutionizing the field of genome manipulation, so there is a need in the art for additional Class 2 CRISPR/Cas systems (e.g., Cas protein plus guide RNA combinations).


Researchers have shown that Class 2 CRISPR Cas protein and their variants can be used in a complex for specific binding and cleavage of DNA. The Class 2 CRISPR Cas complex utilizes a novel RNA and a guide RNA to perform double stranded cleavage of DNA and the complex is expected to have a wide variety of applications in genome editing and nucleic acid manipulation. 

Suggested uses

  • Genome editing
  • Genetic engineering
  • Gene therapy
  • Research tools (e.g., high-throughput screening of gene functions in cell lines and in vivo)
  • Creation of transgenic animal models
  • Genomic imaging



  • Adds additional versatility
  • Variant PAM


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Doudna, Jennifer A.

Other Information


CRISPR, gene editing, genome, gene therapy, cell biology, Class 2

Categorized As

Additional Technologies by these Inventors